Sign In

Login

Password

Forgot Password ? Sign Up

Nityzynon (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nityzynon" in Polish language version.

refsWebsite
Global rank Polish rank
13nih.gov
4th place
7th place
5doi.org
2nd place
6th place
1archive.ph
756th place
32nd place
1scbt.com
low place
5,060th place
1drugbank.ca
4,294th place
205th place
1nejm.org
2,374th place
2,071st place

archive.ph

doi.org

  • Kavana M., Moran GR. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione.. „Biochemistry”. 34 (42), s. 10238–45, wrzesień 2003. DOI: 10.1021/bi034658b. PMID: 12939152. 
  • Santra S., Baumann U. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.. „Expert opinion on pharmacotherapy”. 7 (9), s. 1229–36, maj 2008. DOI: 10.1517/14656566.9.7.1229. PMID: 18422479. 
  • Baumann U., Duhme V., Knerr I., Pronicka E., Auth M.K., Voit P.T. [Lectin-reactive alpha-fetoprotein in tyrosinaemia type I]. „Klinische Pädiatrie”. 3 (217). s. 142–6. DOI: 10.1055/s-2005-836508. PMID: 15858705. 
  • Lock E.A., Gaskin P., Ellis M.K., Robinson M., Provan W.M., Smith L.L. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat.. „Toxicology and applied pharmacology”. 1 (150), s. 125–32, maj 1998. DOI: 10.1006/taap.1998.8404. PMID: 9630461. 
  • Phornphutkul C., Introne W.J., Perry M.B., Bernardini I., Murphey M.D., Fitzpatrick D.L., Anderson P.D., Huizing M., Anikster Y., Gerber L.H., Gahl W.A. Natural history of alkaptonuria.. „The New England journal of medicine”. 26 (347), s. 2111–21, grudzień 2002. DOI: 10.1056/NEJMoa021736. PMID: 12501223. 

drugbank.ca

nejm.org

content.nejm.org

nih.gov

ncbi.nlm.nih.gov

  • Yang DY. 4-Hydroxyphenylpyruvate dioxygenase dioxygenase as a drug discovery target.. „Drug news & perspectives”. 8 (16), s. 493–6, październik 2003. PMID: 14668946. 
  • Kavana M., Moran GR. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione.. „Biochemistry”. 34 (42), s. 10238–45, wrzesień 2003. DOI: 10.1021/bi034658b. PMID: 12939152. 
  • Ros Viladoms J., Vilaseca Buscà M.A., Lambruschini Ferri N., Mas Comas A., González Pascual E., Holme E. [Evolution of a case of tyrosinemia type I treated with NTBC]. „Anales españoles de pediatría”. 3 (54), s. 305–9, marzec 2001. PMID: 11262262. 
  • Vanden Eijnden S., Blum D., Clercx A., Goyens P., De Laet C., Vamos E. Cutaneous porphyria in a neonate with tyrosinaemia type 1.. „European journal of pediatrics”. 7 (159), s. 503–6, lipiec 2000. PMID: 10923223. 
  • Ros J., Vilaseca M.A., Lambruschini N., Mas A., Lindstedt S., Holme E. NTBC as palliative treatment in chronic tyrosinaemia type I.. „Journal of inherited metabolic disease”. 5 (22), s. 665–6, czerwiec 1999. PMID: 10399099. 
  • Hall M.G., Wilks M.F., Provan W.M., Eksborg S., Lumholtz B. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.. „British journal of clinical pharmacology”. 2 (52), s. 169–77, sierpień 2001. PMID: 11488774. 
  • McKiernan P.J. Nitisinone in the treatment of hereditary tyrosinaemia type 1.. „Drugs”. 6 (66), s. 743–50, 2006. PMID: 16706549. 
  • Santra S., Baumann U. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.. „Expert opinion on pharmacotherapy”. 7 (9), s. 1229–36, maj 2008. DOI: 10.1517/14656566.9.7.1229. PMID: 18422479. 
  • Gissen P., Preece M.A., Willshaw H.A., McKiernan P.J. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.. „Journal of inherited metabolic disease”. 1 (26), s. 13–6, 2003. PMID: 12872835. 
  • Baumann U., Duhme V., Knerr I., Pronicka E., Auth M.K., Voit P.T. [Lectin-reactive alpha-fetoprotein in tyrosinaemia type I]. „Klinische Pädiatrie”. 3 (217). s. 142–6. DOI: 10.1055/s-2005-836508. PMID: 15858705. 
  • Lock E.A., Gaskin P., Ellis M.K., Robinson M., Provan W.M., Smith L.L. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine catabolism in the rat.. „Toxicology and applied pharmacology”. 1 (150), s. 125–32, maj 1998. DOI: 10.1006/taap.1998.8404. PMID: 9630461. 
  • Phornphutkul C., Introne W.J., Perry M.B., Bernardini I., Murphey M.D., Fitzpatrick D.L., Anderson P.D., Huizing M., Anikster Y., Gerber L.H., Gahl W.A. Natural history of alkaptonuria.. „The New England journal of medicine”. 26 (347), s. 2111–21, grudzień 2002. DOI: 10.1056/NEJMoa021736. PMID: 12501223. 

pubmedcentral.nih.gov

scbt.com

datasheets.scbt.com